STAT November 29, 2023
De-Shaine Murray

Many parts of neuroscience research have a race problem. Black people are often excluded from studies due to the texture of their hair, receive erroneous and inaccurate readings due to the melanin content of their skin, and are severely underrepresented in neuroimaging datasets.

Now neurotechnology is undergoing a moment of tremendous change, as Elon Musk’s Neuralink has obtained independent review board approval to conduct its first human trials for the R1 robot and N1 brain implant. That makes it an especially good time to have a frank conversation about who gets to lead innovation in neuroscience, especially within neuroengineering. Getting this wrong has vast consequences.

Those of us in neuroscience are pushing the boundaries of what we can observe with...

Today's Sponsors

Venturous
Got healthcare questions? Just ask Transcarent

Today's Sponsor

Venturous

 
Topics: Clinical Trials, Equity/SDOH, Healthcare System, Medical Devices, Patient / Consumer, Provider, Trends
What tariffs mean for the medical device industry - and who will pay for them?
FDA Debuts a New Communications and Compliance Tool for Device Data Integrity Concerns
Labcorp to buy Opko unit’s cancer test assets for up to $225M
Qualcomm CEO: AI Is the New User Interface for Devices
FTC sues to block merger of device coatings companies

Share This Article